CR1 and malaria: For example, iRBCs inhibit monocyte surface expression of complement receptor 1 (CR1 or CD35), and thus impair phagocytosis of circulating immune complexes that can bind to active C3b and C4b, potentially contributing to inflammatory pathology in malaria (19).